translocase of outer mitochondrial membrane 7Genealiases: GMPGS · TOM7
Q-omics provides the consensus-scored TOMM7 profile across patient tissues and cancer cell-line models. TOMM7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TOMM7 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TOMM7 protein abundance shows 17,995 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight SCLC, KIRC, and COAD as cancer lineages where TOMM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOMM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOMM7 survival associations across molecular data types. TOMM7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOMM7 RNA expression–survival associations across cancer types. High TOMM7 expression shows unfavorable associations in SCLC, HNSC, ACC, BLCA and KICH, but favorable associations in MESO. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TOMM7 RNA expression.
This table summarizes TOMM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TOMM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOMM7 shows lower tumor expression in BLCA, UCEC and BRCA and higher tumor expression in KIRC, LIHC and COAD. The KIRC box plot shows higher TOMM7 RNA expression in tumor versus normal tissue (log2 FC = +0.645, t-test p < 0.001).
This table shows molecular features associated with TOMM7 in patient tissues and cancer cell lines. In patient samples, TOMM7 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TOMM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
